CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Weekly AssessmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug516 Monitoring Visit - Week 8 Wiki 1.00
drug514 Monitoring Visit - Baseline Wiki 1.00
drug515 Monitoring Visit - Week 4 Wiki 1.00
drug368 Hydroxychloroquine - Daily Dosing Wiki 1.00
drug370 Hydroxychloroquine - Weekly Dosing Wiki 0.71
drug627 Placebo oral tablet Wiki 0.22

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study

The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Metro Detroit, Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.

NCT04341441 COVID-19 Coronavirus Coronavirus Infections SARS-CoV 2 Drug: Hydroxychloroquine - Daily Dosing Drug: Hydroxychloroquine - Weekly Dosing Other: Placebo oral tablet Diagnostic Test: Monitoring Visit - Baseline Diagnostic Test: Monitoring Visit - Week 4 Diagnostic Test: Monitoring Visit - Week 8 Other: Weekly Assessment
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Plan statistical analyses will include the assumption that up 10% of HCW at risk will become infected if no prophylactic treatment is provided. Therefore we expect that HCQ treatment arm will provide a reduction in the number of SARS-CoV 2 infections by 30%, with an expected study retention rate of 90%, a sample size of ~1500 participants per group, will have an 80% power to detect the difference at p=0.05.

Measure: Reduction in the number of COVID-19 infections in healthcare workers.

Time: 8 Weeks


No related HPO nodes (Using clinical trials)